BARD1 Life Sciences Ltd (ASX:BD1) has been issued a patent in Israel for detecting BARD1 isoforms (proteins) in lung and colorectal cancer.
The company’s proprietary technology platform, BARD1, is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers.
The new patent protects the methods for detecting the presence of the specific BARD1 isoforms and methods for treating and/or preventing lung cancer and colorectal cancer.
Commercialising the company’s diagnostic test
The BARD1 lung test is in development for the early detection of lung cancer.
The company is currently in discussions with a number of contract laboratory organisations to transfer its work to date to a commercial platform.
This will enable the BARD1 tests to be performed by most hospital and independent clinical laboratories around the world.
Leading cause of cancer death in Australia
Lung cancer is the fifth most common cancer and the leading cause of cancer death in Australia.
The Australian Institute of Health and Welfare (AIHW) estimates that there will be 12,741 new cases of lung cancer diagnosed (9.2% of all new cancers diagnosed) and 9,198 deaths from lung cancer (18.9% of all cancer deaths) in Australia in 2018.
Early detection of lung cancer can save people’s lives
Lung cancer is often diagnosed at a later stage after it has spread to other parts of the body, resulting in a 15.8% chance of survival after 5-years in Australia.
Early detection of lung cancer has the potential to save people’s lives by enabling earlier treatment when it is potentially curable.
There is currently no approved blood test available for screening of lung cancer in people without symptoms.
BARD1’s patent portfolio comprises five patent families with multiple granted and pending patents across key marketplaces including the US, Europe and Japan.